Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... [Yahoo! Finance]
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: Yahoo! Finance
4 min read In This Article RARE Total Revenue (2024): $560 million, representing 29% growth over 2023. Crysvita Revenue (2024): $410 million, with 25% growth over 2023. Dojolvi Revenue (2024): $88 million, representing 25% growth over 2023. Evkeeza Revenue (2024): $32 million. Mepsevii Revenue (2024): $30 million. Total Operating Expenses (2024): $1.1 billion. R&D Expenses (2024): $698 million. SG&A Expenses (2024): $322 million. Net Loss (2024): $569 million or $6.29 per share. Cash Equivalents and Marketable Securities (End of 2024): $745 million. Net Cash Used in Operations (2024): $414 million. 2025 Revenue Guidance: Expected between $640 million and $670 million, representing 14% to 20% growth over 2024. Crysvita Revenue Guidance (2025): Expected between $460 million and $480 million, representing 12% to 17% growth over 2024. Dojolvi Revenue Guidance (2025): Expected between $90 million and $100 million, representing 2% to 14% growth over 2024.
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Ultragenyx Pharmaceutical (RARE): Reassessing Valuation After Recent Share Price Rebound [Yahoo! Finance]Yahoo! Finance
- Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? [Yahoo! Finance]Yahoo! Finance
- Ultragenyx (RARE): Assessing Valuation as Revenue Growth and Clinical Progress Fuel Renewed Investor Interest [Yahoo! Finance]Yahoo! Finance
- Ultragenyx to Participate in Investor Conferences in DecemberGlobeNewswire
RARE
Earnings
- 11/4/25 - Miss
RARE
Sec Filings
- 12/11/25 - Form 4
- 12/10/25 - Form 144
- 11/5/25 - Form SCHEDULE
- RARE's page on the SEC website